˫����������H�͸�Ѫѹ

同型半胱氨酸升高是心脑血管疾病的独立预测因素,且与脑卒中关系更密切。伴有血浆同型半胱氨酸浓度升高(>10μmol/L)的高血压被定义为H型高血压,约占我国成年高血压患者的75%。H型高血压的治疗应双管齐下,同时降低血压和血浆同型半胱氨酸浓度。降低同型半胱氨酸最有效的方法是补充叶酸,但同型半胱氨酸降低后是否减少了卒中、冠心病等心脑血管事件仍存在着争议,目前倾向于在一级预防人群中可能有益。携带MTHFR-C677TT基因型的H型高血压患者基线血浆同型半胱氨酸高,可能需强化治疗。     

同型半胱氨酸、胱抑素C水平与高血压病及高血压脑出血的相关性

目的 研究同型半胱氨酸、胱抑素C与高血压病及高血压脑出血的相关性。方法 将研究对象分为高血压脑出血组（108例）、单纯高血压组（100例）和正常对照组（100例）,检验其血中同型半胱氨酸、胱抑素C、总胆固醇、甘油三酯水平。结果 高血压脑出血组及单纯高血压组同型半胱氨酸、胱抑素C水平高于正常对照组,差异有统计学意义（P<0.05）。高血压脑出血组同型半胱氨酸、胱抑素C水平高于单纯高血压组,差异有统计学意义（P<0.05）。同型半胱氨酸、胱抑素C与总胆固醇、甘油三酯均无相关性（P＞0.05）。结论 监测同型半胱氨酸、胱抑素C水平对早期防治高血压及脑出血有重要意义。     

伴同型半胱氨酸升高的高血压——“H型”高血压

高同型半胱氨酸血症是冠状动脉粥样硬化性心脏病、脑卒中等心脑血管疾病的危险因素,伴有血浆同型半胱氨酸水平升高的高血压被定义为＂H型＂高血压,约占我国成年高血压患者的75%。＂H型＂高血压的治疗应同时降低血压和血浆同型半胱氨酸的水平。降低同型半胱氨酸最有效的方法是补充叶酸,并可能减少心脑血管事件的发生。     

原发性高血压病人血清同型半胱氨酸浓度变化的观察

目的 检测血清同型半胱氨酸(Hcy)水平变化,探讨原发性高血压与同型半胱氨酸浓度的关系.方法 用循环酶法Hcy试剂盒检测50名健康对照者和176例原发性高血压病人的血清同型半胱氨酸浓度.结果 高血压1级、2级血清同型半胱氨酸的浓度与对照组比较差异无统计学意义(P＞0.05);高血压3级与对照组和1级、2级组比较差异均有统计学意义(P＜0.01).结论 血清同型半胱氨酸水平对评估高血压的病情进展、危险分层具有一定的意义.     

H型高血压临床研究进展

高血压合并高同型半胱氨酸血症是发生脑卒中的重要危险因素,控制血压的同时降低同型半胱氨酸可减少脑卒中发生率。目前已知降低同型半胱氨酸最安全有效的方法是补充叶酸,早期关注同型半胱氨酸水平并检测基因型进行积极干预,将推动我国高血压个体化防治的发展,降低高危患者脑卒中风险。     

血浆同型半胱氨酸水平对原发性高血压患者冠心病发生的相关性研究

目的 探讨血浆同型半胱氨酸水平对原发性高血压患者发生冠心病的预测价值。方法 选择接受冠状动脉造影检查的原发性高血压患者251例,根据冠脉造影情况分为单纯高血压组(120例)和高血压合并冠心病组(131例),分析高血压患者血浆同型半胱氨酸水平,比较不同同型半胱氨酸水平患者冠心病的发病率,并通过logistic回归分析原发性高血压患者发生冠心病的危险因素。结果 高血压合并冠心病组患者血浆同型半胱氨酸水平和低密度脂蛋白水平高于单纯高血压患者,而高密度脂蛋白水平低于单纯高血压患者,差异均有统计学意义(P<0.05);血浆同型半胱氨酸水平(OR=4.503,P<0.05)和低密度脂蛋白水平(OR=3.509,P<0.05)是原发性高血压发生冠心病的独立危险因素。高密度脂蛋白可以降低原发性高血压患者发生冠心病的风险(OR=0.439,P<0.05)。结论 血浆同型半胱氨酸水平升高发生冠心病的可能性越大。     

原发性高血压患者同型半胱氨酸水平与动脉病变及左心室肥厚关系的临床研究

目的:研究原发性高血压患者血浆同型半胱氨酸(Hcy)水平与动脉病变及左心室肥厚的关系。方法:将384例原发性高血压(高血压组)患者分为高血压1级者82例,高血压2级者196例,高血压3级者106例,另选79例健康体检人员为对照组,比较各组血浆同型半胱氨酸水平及颈动脉内中膜厚度及斑块情况,并根据超声心动图结果将高血压患者分为左心室肥厚者(258例)及无左心室肥厚者(126例),比较两者血浆同型半胱氨酸水平。结果:高血压组与对照组血浆同型半胱氨酸及颈动脉内中膜厚度组间比较差异均有统计学意义(P均0.001),随高血压严重程度的加重,血浆同型半胱氨酸及颈动脉内中膜厚度均出现升高;高血压2级者、3级者的颈动脉斑块发生率高于1级者、对照组,差异均有统计学意义(P均0.001);左心室肥厚的高血压患者血浆同型半胱氨酸水平高于无左心室肥厚的高血压患者,差异有统计学意义(P0.001)。结论:同型半胱氨酸与原发性高血压的发病及进展关系密切,血浆同型半胱氨酸的水平可反映原发性高血压患者动脉病变及左心室肥厚病情的严重程度。     

同型半胱氨酸检测在H型高血压中的作用

目的探究同型半胱氨酸检测在H型高血压中的作用。方法随机抽取我院自2015年1月~2016年1月收治的原发性高血压患者52例作为A组[3级高血压组(n=10)、2级高血压组(n=30)、1级高血压组(n=12)],另随机抽取同期在我院门诊体检的健康人员52例作为B组。检测并分析A、B两组的血浆同型半胱氨酸水平以及高同型半胱氨酸血症患者所占的百分比。结果 A组患者的同型半胱氨酸水平明显高于B组的,A组中高同型半胱氨酸血症患者的占比(88.4%)明显高于B组的(7.7%),差异显著(P0.05);血压越高,同型半胱氨酸水平越高,高同型半胱氨酸血症的发生率也越高。结论同型半胱氨酸检测在H型高血压中具有较高的诊断价值,有助于临床医师更好的为患者诊疗疾病。     

同型半胱氨酸水平与高血压、高血压合并脑卒中的关系探析

目的分析同型半胱氨酸水平和高血压、高血压合并脑卒中之间的关系。方法选取2014年9月~2015年9月我院收治的高血压患者94例作为研究对象,其中高血压合并脑卒患者31例作为A组,其他均为单纯的高血压患者63例作为B组,选取同时在我院接受体验的健康人员94例为C组,对比三组人员的同型半胱氨酸水平。结果 B组患者的同型半胱氨酸水平显著高于A组与C组,差异有统计学意义(P0.05)。结论同型半胱氨酸不但是高血压发生的高危因素,而且高同型半胱氨酸还是高血压患者出现脑卒中,与动脉粥样硬化的独立性因素。     

血浆同型半胱氨酸与冠心病及高血压的相关性研究

目的探讨冠心病及高血压患者中,血浆同型半胱氨酸、一氧化氮水平的变化。方法对99例冠心病患者(冠心病组)与122例单纯高血压患者(高血压组)进行血浆同型半胱氨酸、一氧化氮水平的测定。结果冠心病组血浆同型半胱氨酸浓度为(18.57±7.47)μmol/L,明显高于高血压组(14.53±10.58)μmol/L(P0.01)。冠心病组血清一氧化氮浓度为(51.15±18.78)μmol/L,明显低于高血压组(70.39±41.55)μmol/L(P0.001)。结论高同型半胱氨酸血症与冠心病的发生有密切关系,并且同型半胱氨酸水平与一氧化氮呈反比,可能同型半胱氨酸水平与血管损伤的严重程度有明显的相关性。     

血浆同型半胱氨酸水平与脑大动脉粥样硬化性病变的相关性分析

目的探讨血浆总同型半胱氨酸（Hcy）水平与脑大动脉粥样硬化性病变的相关性。方法对行数字减影血管造影（DSA）的276例缺血性脑卒中患者进行分组,具有颅内外大动脉粥样硬化性狭窄（至少1支血管狭窄率〉50％）的224例患者为狭窄组,无狭窄或轻度狭窄（狭窄率≤50％）患者52例为对照组。对两组患者血浆总Hcy水平及脑卒中的常规危险因素如年龄、性别、高血压、糖尿病、长期吸烟、长期饮酒、血甘油三酯、高密度脂蛋白（HDL）、低密度脂蛋白水平等进行了分析。结果脑大动脉粥样硬化性狭窄组血浆Hcy升高的比例明显大于对照组（分别为38．8％及15．4％;OR3．49,95％CI 1．57～7．77,P=0．001）。多元逐步logistic回归分析发现,血浆Hcy水平升高是脑大动脉粥样硬化性狭窄独立的危险因子（OR=4．10,95％CI：1．80～9．32,P=0．001）。血浆Hcy升高与高血压、高龄及HDL降低合并存在时,其发生脑大动脉粥样硬化性狭窄的风险性增加（OR值分别4．89、4．79和10．46）。结论来自DSA的结果提示,血浆Hcy水平升高是脑大动脉粥样硬化性病变独立且强烈的危险因子;与其他危险因子并存,发生脑大动脉粥样硬化性病变的风险性增加。     

Homocysteine, hypertension and stroke.

The balance of evidence from observational studies suggests that elevated homocysteine levels are associated with increased risk of carotid artery disease and stroke. There is however a paucity of prospective studies. There are also concerns regarding confounding due to factors associated with hyperhomocysteinemia, including renal impairment, an atherogenic diet and cigarette smoking. Homozygosity for a defective thermolabile variant of MTHFR, a common genetic polymorphism which results in hyperhomocysteinemia, has not been consistently linked with stroke or other vascular disease. There is a need for additional prospective studies with data on relevant confounders, sufficient power to characterise the form of the association between homocysteine concentrations and stroke risk, whether linear or threshold, and power to study interactions between homocysteine, other dietary markers and established stroke risk factors such as smoking and hypertension. Similarly, the evidence linking hyperhomocysteinemia with hypertension is limited and inconsistent. Given the biological mechanisms proposed in support of the homocysteine-CVD hypothesis, one would predict a positive association between homocysteine and blood pressure. There is a need to address this hypothesis directly in studies with reliable measurements of both homocysteine and blood pressure. Ultimately, the case for a causal role for elevated homocysteine levels in vascular disease, including hypertension and stroke, will depend on data from randomised controlled trials of homocysteine lowering interventions. Given the high prevalence of hyperhomocysteinemia in apparently well nourished populations and the tendency for homocysteine concentrations to increase with age, modest effects of homocysteine on stroke risk will have profound implications for public health.     

血浆同型半胱氨酸与青中年脑卒中关系的探讨

目的探讨血浆同型半胱氨酸（Homocysteine，Hcy）水平与青、中年脑卒中及其不同类型、类别之间的关系。方法采用高压液相分析原理分别测定248例青中年脑卒中患者及212例正常健康青中年对照者血浆Hcy水平。结果全部脑卒中患者血浆Hcy水平均高于同年龄段健康对照组（P〈0．01），其中青年脑卒中患者血浆Hcy水平又高于中年患者（P〈0．05），同年龄组青年、中年脑梗死患者与脑出血患者血清Hcy水平比较差异无显著性意义（P〉0．05），全部脑梗死患者与全部脑出血患者Hcy水平比较，差异亦无显著性意义（P〉0．05），青、中年缺血性脑卒中组中以大动脉粥样硬化性卒中的平均Hcy水平为最高，与其他类别组比较差异有意义（P〈0．05）。结论高HCY血症是是青、中年脑卒中的独立危险因素，是大动脉粥样硬化性卒中重要病因，Hcy对青年脑卒中影响比中年大。     

Homocysteine and risk of stroke.

The balance of evidence from observational studies suggests that elevated levels of homocysteine are associated with increased risk of carotid artery disease and stroke. There is, however, a paucity of prospective studies. There are also concerns regarding confounding caused by factors associated with hyperhomocysteinaemia, including renal impairment, an atherogenic diet and cigarette smoking. Homozygosity for a defective thermolabile variant of methylene-tetrahydrofolate reductase, a common genetic polymorphism which results in hyperhomocysteinaemia, has not been consistently linked with stroke or other vascular diseases. Additional prospective studies are required, with sufficient power to characterise the form of the association between homocysteine concentrations and stroke risk, whether linear or threshold, and to study interactions between homocysteine, other dietary markers and established stroke risk factors such as smoking and hypertension. Ultimately, the case for a causal role for elevated levels of homocysteine in vascular disease, including stroke, will depend on data from randomised controlled trials of homocysteine-lowering interventions. Given the high prevalence of hyperhomocysteinaemia in apparently well-nourished populations and the tendency for homocysteine concentrations to increase with age, modest effects of homocysteine on stroke risk will have profound implications for public health.     

同型半胱氨酸与脑卒中患者脑白质病变的相关性研究

目的探讨脑卒中患者的血浆同型半胱氨酸(Hcy)水平与脑白质病变(WML)的关系。方法选择急性脑卒中患者11 5例,根据Ylikoski评分,将患者分为重度WML组59例(Ylikoski评分>17分),无或轻度WML组56例(Ylikoski评分≤17分)。测定患者血浆Hcy水平,进行多因素1ogistic回归分析。结果重度WML组患者的年龄、血浆Hcy水平和高血压的比例均高于无或轻度WML组,差异有统计学意义(P<0.05)。剔除年龄等因素影响后,血浆Hcy水平仍是重度WML的独立危险因素(OR=2.959,95%CI:1.164～7.518,P=0.023)。结论高Hcy血症是脑卒中患者出现重度WML的独立危险因素。     

Fractions of total plasma homocysteine in patients with ischemic stroke before the age of 55 years

The mechanism responsible for the association between elevated circulating homocysteine levels and ischemic stroke remains unclear. Therefore, the authors assessed total plasma homocysteine (tHcy) and its fractions (free [fHcy] and protein-bound [bHcy] homocysteine) in patients with ischemic stroke before the age of 55 years. Fifty patients (23 men, mean age 46.8+/-7.6 years) with ischemic stroke or transient ischemic attacks, with symptoms lasting < 72 hours were enrolled. In this group: 32 (64%) patients had hypertension; 12 (24%), ischemic heart disease (IHD); and 20 (40%), type 2 diabetes mellitus (DM). The control group consisted of 30 matched healthy individuals (17 men, mean age 44.6+/-6.2 years). The tHcy, fHcy, and bHcy levels were determined by high-performance liquid chromatography. tHcy and its fractions did not differ significantly between patients and controls. However, stroke patients with hypertension had significantly higher concentrations of tHcy and bHcy compared to stroke patients without hypertension (tHcy 13.0+/-3.3 vs 10.7 +/-3.2 micromol/L, p < 0.05; bHcy 9.7+/-2.6 vs 7.8+/-2.3 micromol/L, p < 0.01, respectively); fHcy was borderline significant: 3.1 (1.5-6.5) vs 2.5 (1.8-5.3) micromol/L, p = 0.05. The presence of IHD, DM, hyperlipoproteinemia, clinical subtypes of stroke, smoking, and family history of stroke did not influence these parameters. In the group of 50 patients, tHcy correlated with mean systolic blood pressure (BP) (r = 0.3, p < 0.05) and bHcy correlated with mean systolic and mean diastolic BP (r = 0.3, p < 0.05). These findings suggest an association between hypertension and redox status of Hcy in patients with ischemic stroke before the age of 55 years. This observation supports the hypothesis that elevated BP may contribute to Hcy-related vascular injury.     

血清同型半胱氨酸水平与颈动脉粥样硬化关系的分析

目的探讨血清同型半胱氨酸(HCY)水平与颈动脉粥样硬化的相关性,以及与高血压、糖尿病、高脂血症等动脉粥样硬化性血管病(ASVD)危险因素的关系.方法选取住院患者97例,用酶联免疫吸附法(ELISA)测定血清HCY水平,用彩色多普勒超声仪行颈动脉壁内膜-中膜厚度(IMT)、动脉斑块积分检查.结果血清HCY水平与颈动脉IMT、动脉斑块积分呈正相关,与高血压、糖尿病、高脂血症无关.结论血清同型半胱氨酸水平与颈动脉粥样硬化密切相关,与高血压、糖尿病、高脂血症等动脉粥样硬化性血管病危险因素无直接关系,血清HCY水平是动脉粥样硬化的一个独立危险因素.